REPLIMUNE GROUP, INC. Preferred Stock, Value, Outstanding
REPLIMUNE GROUP, INC. (REPL) had Preferred Stock, Value, Outstanding of $0 as of 2020-12-31, per its 10-Q filed 2021-02-04.
Discontinued › Balance Sheet › Equity
us-gaap:PreferredStockValueOutstanding · last filed 2021-02-04
- 2020-12-31: Preferred Stock, Value, Outstanding $0.00.
- 2020-09-30: Preferred Stock, Value, Outstanding $0.00.
- 2020-06-30: Preferred Stock, Value, Outstanding $0.00.
- 2020-03-31: Preferred Stock, Value, Outstanding $0.00.
| Period end | Preferred Stock, Value, Outstanding |
|---|---|
| 2020-12-31 | $0.00 10-Q · filed 2021-02-04 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-07 |
| 2020-03-31 | $0.00 10-Q · filed 2021-02-04 |
| 2019-12-31 | $0.00 10-Q · filed 2020-02-13 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-12 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-14 |
| 2019-03-31 | $0.00 10-K · filed 2019-06-28 |
| 2018-12-31 | $0.00 10-Q · filed 2019-02-14 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |